New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
17:20 EDTMS, GILDFormer Morgan Stanley adviser charged in insider case, Bloomberg says
Former Morgan Stanley (MS) broker Kevin Dowd has been charged with insider trading related to Gilead's (GILD) $11B acquisition of Pharmasset in 2011, according to a Bloomberg report. Reference Link
News For MS;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
12:46 EDTMSFederal Reserve approves final rule for capital plan and stress test regulations
Subscribe for More Information
November 24, 2015
15:05 EDTMSFed to provide means for banks examiners to express divergent views
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB BAC DIS NFLX X YNDX GILD PANW SUNW
November 23, 2015
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
06:41 EDTGILDGilead granted marketing authorization in EU for Genvoya
Subscribe for More Information
November 18, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
08:55 EDTMSMorgan Stanley exec sees Q4 not much better than Q3 for banks, DJ reports
Morgan Stanley (MS) Institutional Securities President Colm Kelleher cautioned that fixed-income markets "still seem subdued," according to Dow Jones, citing his comments at an investment conference. Morgan Stanley was among the banks that reported lower revenue from fixed-income, currency and commodities trading during the third quarter and Kelleher said he doesn't think "the fourth quarter is going to be much better," the report noted. Large bank peers to Morgan Stanley include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
November 17, 2015
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
09:44 EDTMSBrookings Institute to hold a discussion
The Hutchins Center on Fiscal and Monetary Policy at Brookings and Ben Bernanke host a discussion with Betsy Graseck of Morgan Stanley, Governor Tarullo of the Federal Reserve on the role of collateral in the financial system, liquidity in bond markets and the shadow banking system in a meeting being held in Washington, D.C. on November 17 at 1:30 pm. Webcast Link
07:48 EDTMSBofa/Merrill to hold a conference
Banking & Financial Services Conference 2015 is being held in New York on November 17-18.
November 16, 2015
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information
November 13, 2015
08:26 EDTMSFederal Reserve Board to hold a conference
Subscribe for More Information
November 12, 2015
17:55 EDTGILDGilead announces FDA approval of Harvoni
Gilead Sciences announced that the U.S. FDA has approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection and in patients co-infected with HIV. In addition, Harvoni plus ribavirin for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment-experienced, genotype 1 patients with cirrhosis. Harvoni received regulatory approval for the treatment of chronic HCV genotype 1 infection in adults in the United States in October 2014.
06:12 EDTMSMorgan Stanley to offer wealth management clients savings accounts, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use